Publications
Publications

Impax Laboratories: Executing Accretive Acquisitions (B)

By: Benjamin C. Esty and Daniel Fisher
  • Format:Print
  • | Language:English
  • | Pages:2
ShareBar

Abstract

Explores events after Impax announced the acquisition of a portfolio of generic pharmaceutical products from Teva in June 2016.

Keywords

Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States

Citation

Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Acquisitions (B)." Harvard Business School Supplement 220-031, October 2019.

About The Author

Benjamin C. Esty

Finance
More Publications

More from the Authors